Tech Company Financing Transactions
Osanni Bio Funding Round
On 6/23/2026, Osanni Bio announced $190 million in Series B funding from Patient Square Capital, Horowitz Group and Invus Opportunities.
Transaction Overview
Company Name
Announced On
6/23/2026
Transaction Type
Venture Equity
Amount
$190,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to advance its current pipeline of multiple programs and scale its discovery and development process.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
345 California Street 600
San Francisco, CA 94104
USA
San Francisco, CA 94104
USA
Phone
Undisclosed
Website
Email Address
Overview
Osanni Bio is a development-stage therapeutics company reinventing the discovery and development of new medicines. We unite biodesign-inspired innovation, technology, and capital efficiency to maximize our impact on the future of human health. We are reinventing the process of discovery by approaching the science of disease with modern technology and a beginner's mindset. Inspired by the principles of biodesign, we drive capital-efficient development of life-changing medicines for patients and the physicians who care for them.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Michael Ackermann
Chief Scientific Officer
John Paderi
VP - Bus. Development
Dawn Koffler
VP - Human Resources
Cora Versaggi
VP - Manufacturing
Aswin Sundaram
Browse more venture capital transactions:
Prev: 6/23/2026: Ubotica Technologies venture capital transaction
Next: 6/23/2026: Adomate venture capital transaction
Share this article
Where The Data Comes From
We report on every notable VC transaction. VC investment data records reported here are derived from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs